Home Cart Sign in  
Chemical Structure| 1086062-66-9 Chemical Structure| 1086062-66-9

Structure of Omipalisib
CAS No.: 1086062-66-9

Chemical Structure| 1086062-66-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2 , respectively.

Synonyms: GSK2126458; GSK458

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Omipalisib

CAS No. :1086062-66-9
Formula : C25H17F2N5O3S
M.W : 505.50
SMILES Code : O=S(C1=CC=C(F)C=C1F)(NC2=CC(C3=CC=C4N=CC=C(C5=CC=NN=C5)C4=C3)=CN=C2OC)=O
Synonyms :
GSK2126458; GSK458
MDL No. :MFCD16038929
InChI Key :CGBJSGAELGCMKE-UHFFFAOYSA-N
Pubchem ID :25167777

Safety of Omipalisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Omipalisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    p110γ, Ki:0.06 nM

  • p110β

    p110β, Ki:0.13 nM

  • p110α

    p110α, Ki:0.019 nM

  • p110δ

    p110δ, Ki:0.024 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
IPF lung fibroblasts 0.84 nM (C-LF), 1.52 nM (IPF-LF) 30 minutes GSK2126458 inhibited serum-induced Akt phosphorylation PMC4975851
IPF lung fibroblasts 18.70 nM (C-LF), 23.64 nM (IPF-LF) 72 hours GSK2126458 inhibited serum-induced fibroblast proliferation PMC4975851
IPF bronchoalveolar lavage fluid cells 0.58 nM 30 minutes GSK2126458 inhibited Akt phosphorylation PMC4975851
uveal melanoma cells 0-1 µM 3 hours To assess the effect of MEK or PI3K inhibitors on the phosphorylation of MAPK and AKT, results showed that MEK or PI3K inhibitors caused the loss of phosphorylation of their respective downstream targets at low nanomolar concentrations. PMC3935730
uveal melanoma cells 0-500 nM (MEKi), 0-1000 nM (PI3Ki) over time To evaluate cell growth through real-time impedance measurements, results showed that MEKi treatment led to a significant reduction in impedance in GNAQ mutant cells, while PI3Ki treatment caused impedance reduction in both mutant and wild-type cells. PMC3935730
SBC2 cells 50 nM 12 hours To investigate the antitumor activity of PI3K/mTOR inhibitors on SBC2 cells, results showed that BEZ235 and GSK2126458 significantly inhibited cell proliferation and increased apoptosis PMC10558571
H446 cells 50 nM 12 hours To investigate the antitumor activity of PI3K/mTOR inhibitors on H446 cells, results showed that BEZ235 and GSK2126458 significantly inhibited cell proliferation and increased apoptosis PMC10558571
HS01 cells 39-156 nM 24 hours Omipalisib and dasatinib synergized in HS01 cells to reduce cell viability and inhibit phosphorylation of AKT and FAK/SFK PMC10832398
HS02 cells 39-156 nM 24 hours Omipalisib and dasatinib synergized in HS02 cells to reduce cell viability and inhibit phosphorylation of AKT and FAK/SFK PMC10832398
TSC2-null LAM patient-derived angiomyolipoma 621-102 cells 500 nM 16-18 hours Omipalisib inhibited the phosphorylation of pS6, p4E-BP1, and pAkt, and reduced the growth of TSC2-null cells. PMC7022412
Mouse Tsc2-null TTJ-L cells 500 nM 16-18 hours Omipalisib inhibited the phosphorylation of pS6, p4E-BP1, and pAkt, and reduced the growth of TSC2-null cells. PMC7022412
MCF-7 cells 1,000 nM 72 hours To evaluate the apoptotic effect of BEZ235 on MCF-7 cells, results showed that at the highest concentration, BEZ235 significantly induced PARP cleavage, indicating the occurrence of apoptosis. PMC3127046
TamR7 cells 1,000 nM 72 hours To evaluate the apoptotic effect of BEZ235 on TamR7 cells, results showed that at the highest concentration, BEZ235 significantly induced PARP cleavage, indicating the occurrence of apoptosis. PMC3127046

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CgrpCreER;TKO mice Oral Idasanutlin 40 mg/kg, Navitoclax 100 mg/kg Idasanutlin: 5 days on, 2 days off, for 14 days; Navitoclax: daily for 14 days To investigate the antitumor efficacy of PI3K/mTOR inhibitors in mouse models, results showed that BEZ235 combined with radiation significantly inhibited tumor growth PMC10558571
Mice FGFR4V550E-driven RMS model Oral 0.5 µmol/L once daily for 3 days To evaluate the inhibitory effect of Omipalisib on the growth of FGFR4V550E-driven RMS tumors, results showed that Omipalisib significantly inhibited tumor growth and improved survival PMC8054765
NSG mice orthotopic allograft schwannoma model oral gavage 10 mg/kg Once daily, 5 days per week for 5 weeks The combination of omipalisib and dasatinib significantly reduced intraneural growth of mouse allograft tumors over a two-week period PMC10832398

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01725139 Idiopathic Pulmonary Fibrosis Phase 1 Completed - United Kingdom ... More >> GSK Investigational Site London, United Kingdom, SW3 6NP Less <<
NCT00972686 Solid Tumours PHASE1 COMPLETED 2015-03-31 GSK Investigational Site, San ... More >>Francisco, California, 94115, United States|GSK Investigational Site, New Brunswick, New Jersey, 08901, United States|GSK Investigational Site, Chapel Hill, North Carolina, 27599-7600, United States|GSK Investigational Site, Dallas, Texas, 75246, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, Salt Lake City, Utah, 84112-5550, United States|GSK Investigational Site, Seattle, Washington, 98109, United States|GSK Investigational Site, Amsterdam, 1066 CX, Netherlands|GSK Investigational Site, Utrecht, 3584 CX, Netherlands Less <<
NCT01248858 Cancer Phase 1 Terminated(The reason for term... More >>ination was lack of tolerability and efficacy of the combination treatment) Less << - United States, North Carolina ... More >> GSK Investigational Site Chapel Hill, North Carolina, United States, 27599-7305 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Canada, Ontario GSK Investigational Site Toronto, Ontario, Canada, M5G 2M9 Italy GSK Investigational Site Milano, Lombardia, Italy, 20132 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.89mL

1.98mL

0.99mL

19.78mL

3.96mL

1.98mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories